Nurix Therapeutics, Inc. NRIX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -340.2%+50.4pp | -390.5%-189pp | -201.4%+275pp | -476%-79.8pp | |
| Net margin | -314.9%+39.9pp | -354.9%-168pp | -187%+280pp | -466.9%-73.0pp | |
| EBITDA margin | -329.8%+43.7pp | -373.4%-182pp | -191.6%+270pp | -462%-74.8pp | |
| Free cash flow margin | -313.7%+19.7pp | -333.4%— | —— | -445.4%-143pp | |
| Returns | |||||
| Return on equity | -49.6%+3.6pp | -53.2%+3.9pp | -57.1%-1.3pp | -55.8%-18.8pp | |
| Return on assets | -39%-1.2pp | -37.8%-0.5pp | -37.3%+3.1pp | -40.4%-13.5pp | |
| Return on invested capital | -72.2%-3.5pp | -68.7%+4.1pp | -72.8%-2.8pp | -70%-18.8pp | |
| Efficiency | |||||
| Asset turnover | 0.1×0.0× | 0.1×-0.1× | 0.2×+0.1× | 0.1×0.0× | |
| Liquidity | |||||
| Current ratio | 7×+0.6× | 6.5×+3.1× | 3.4×-1.1× | 4.5×-0.2× | |
| Quick ratio | 7×+0.6× | 6.5×+3.1× | 3.4×-1.1× | 4.5×-0.2× | |
| Cash ratio | 2.9×+1.7× | 1.2×+0.5× | 0.6×-0.3× | 0.9×-0.3× | |
| Leverage | |||||
| Debt-to-equity | 0.1×0.0× | 0.1×-0.1× | 0.2×+0.1× | 0×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0×0.0× | 0.1×+0.1× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $6.22-20.8% | $7.85+113% | $3.69-40.9% | $6.25-21.7% | |
| Valuation | |||||
| Market capitalization | $1.79B+11.4% | $1.61B+371% | $341.5M-49.0% | $669.41M-48.0% | |
| Enterprise value | $1.6B+4.8% | $1.53B+382% | $316.59M-48.6% | $616M-49.5% | |
| Price / sales | 21.3×-8.2× | 29.5×+25.1× | 4.4×-12.9× | 17.3×-26.0× | |
| Price / book | 3.3×+0.3× | 3.1×+1.4× | 1.7×-0.5× | 2.2×-1.6× | |
| EV / sales | 19.1×-8.9× | 28×+23.9× | 4.1×-11.8× | 15.9×-25.1× | |
| Free cash flow yield | -14.7%-3.4pp | -11.3%— | —— | -25.7%-18.7pp | |
| Earnings yield | -14.8%-2.7pp | -12%+30.1pp | -42.2%-15.2pp | -26.9%-17.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Nurix Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Nurix Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.